You are unlikely to read much about this in the Guardian however -
https://europepmc.org/article/PPR/PPR303143
Why COVID-19 is not so spread in Africa:
"
Conclusions
The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality. "
Onchocerciasis is better known as river blindness.
The importance of the body's T cell response as contrasted with in vitro antibody production is also under-reported -
https://www.cebm.net/covid-19/what-...n-why-immunity-is-about-more-than-antibodies/
"
Potential for long-term immunity
Early research suggests that the antibodies in people infected with SARS-CoV-2 dropped significantly within 2 to 3 months [
21,
22], causing concern that humoral immunity against the virus may decline rapidly. However, it is a normal part of the immune response that antibody levels fall after an infection has resolved [
23]. For example, in seasonal coronavirus infections, antibodies start to decline at about a week after infection and typically only last for about a year [
24]. It should also be noted that memory T and B cells are formed after infection [
25,
26]; these can be reactivated when another infection with the same virus occurs and could provide long-lasting immunity. A preliminary study that has not yet undergone peer review has shown that memory T and B cells were found in patients with mild COVID-19 symptoms who had recovered and that these cells persisted, suggesting the potential for longer-term immunity."
Incidentally the Astra-Zeneca team are suggesting that their vaccine provides rather good T-cell protection.